ALGS News and Press, Aligos Therapeutics Inc. From 04/27/21

SOUTH SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has appo...

Aligos Therapeutics (ALGS) has started the dosing in the first cohort of chronic hepatitis B (“CHB”) patients in the ongoing ALG-000184-201 study which is designed to evaluate the safety and efficacy of ALG-000184 in patients with CHB.The Phase 1 proof-of-concept study...

SOUTH SAN FRANCISCO, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has star...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Apri...

Aligos Therapeutics (ALGS): Q4 GAAP EPS of -$1.09 misses by $0.19.Cash, Cash Equivalents and investments of $243.5 million as of December 31, 2020.Press Release For further details see: Aligos Therapeutics EPS misses by $0.19

- Advanced ALG-010133 and ALG-000184 into the clinic - both expected to generate safety and antiviral activity data in Chronic Hepatitis B (CHB) patients in 2021 - Listed on NASDAQ Global Select Market under the symbol ALGS and raised $167.2 million in gross proceeds from the Initia...

SOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has star...

SOUTH SAN FRANCISCO, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company delivere...

Gainers: NanoViricides, Inc. (NNVC) +89%.Communications Systems, Inc. (JCS) +74%.Amyris, Inc. (AMRS) +41%.Hovnanian Enterprises, Inc. (HOV) +37%.Rocket Companies, Inc. (RKT) +36%.Perion Network Ltd. (PERI) +27%.The OLB Group, Inc. (OLB) +25%.Novan, Inc. (NOVN) +21%.Aemetis, Inc. (AMTX) +21%.S...

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company will deli...